Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Exact Sciences, NSABP Validating Ability of ctDNA Test to Detect MRD in Colorectal Cancer Patients
The study, called CORRECT-MRD II, is expected to enroll approximately 750 patients at 35 study sites in the US and Canada.
Burning Rock Details Plans for Cancer Monitoring Assay, Adds New Data Supporting Early Detection
Premium
Both the MRD test, BR Prophet, and a six-cancer screening assay, BR Predict, are slated for launch in China next year, initially for contracted hospital customers.
Guardant Health Laying Path for Future in Cancer Screening, Updates Launch Plans for CRC Assay
Premium
The firm said it will release its colorectal cancer test as an LDT next year and has reorganized its leadership to support future growth in the cancer screening market.
Guardant Health Q2 Revenues Grow 39 Percent
The firm's oncology testing revenues outpaced other revenue sources, driven by a more than 50 percent increase in clinical test volume.
Adaptive Biotechnologies Q2 Revenues Jump 83 Percent
Test volume for ClonoSeq, its assay for minimal residual disease monitoring in blood cancers, grew 75 percent year over year and 15 percent sequentially.